Synergy with PD-L1 inhibition therapy (750 μg/kg PD-L1 antibody injected intravenously once every 3 days) in a bilateral CT26 tumor model (Figure 4b) successfully raised the number of infiltrating CD45+ (22.84 ± 2.97% and 21.74 ± 8.32%, respectively), CD4+ (3.15 ± 1.14% and 2.88 ± 1.45%, respectively), CD8+ T (2.60 ± 1.29% and 2.58 ± 1.75%, respectively) cells, and NK cells (3.05 ± 1.11% and 2.19 ± 0.95%, respectively) (Figure 4e–h). The gene discussed is PTPRC; the disease is neoplasm.